Nanotheranostics in evidence based personalized medicine

Current Drug Targets

Volumn 15, Issue 10, 2014, Pages 915-930

  Sharma, Sushil ^a  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

Charnolopathy; Charnolophagy; Charnoly body; Chronopharmacology; Metallothioneins; microRNA; Nanotheranostics; Pegylation; synuclein index

Indexed keywords

ALGINIC ACID; ALPHA SYNUCLEIN; APTAMER; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; CHARNOLY BODY; CHITOSAN; COPOLYMER; DENDRIMER; DOXORUBICIN; DRUG VEHICLE; FIBRONECTIN; GOLD NANOPARTICLE; HYBRID PROTEIN; INTERLEUKIN 10; LIPOSOME; MACROGOL; METALLOTHIONEIN; MICRORNA; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; QUANTUM DOT; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; XANTHAN; NANOMATERIAL;

ALZHEIMER DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CELL THERAPY; CELL TRACKING; CHRONOPHARMACOLOGY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; ENDOCYTOSIS; EPIGENETICS; EVIDENCE BASED MEDICINE; GENE SILENCING; ISOTOPE LABELING; MICRONEEDLE; MICROTECHNOLOGY; MITOCHONDRION; MONONUCLEAR STEM CELL; NANODEVICE; NANOMEDICINE; NANOTECHNOLOGY; NANOTHERANOSTICS; NEOPLASM; NEUROPROTECTION; ORAL IMMUNOTHERAPY; PERSONALIZED MEDICINE; PROTEIN MICROARRAY; PULSATILE DRUG RELEASE; RETICULOENDOTHELIAL SYSTEM; SUSTAINED DRUG RELEASE; CARDIOVASCULAR DISEASES; HUMAN; NEOPLASMS; NEURODEGENERATIVE DISEASES;

CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84925938684     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Sanvicens N, Marco MP. Multifunctional nanoparticles-Properties and prospectus for their use in human medicine. p 425, Elsevier Publishers 2008.
2. Swami A, Shi J, Gadde S, et al. Nanoparticles for targeted and temporally-controlled drug delivery. Chapter 2, S. Svenson and R. K. Prud; home (eds) Multifunctional Nanoparticles for Drug Delivery Applications: Imaging, Targetting, and Delivery. Nanostructure Science and Technology 9-29. Springer Verlag Publishers 2012.
3. "Nanotechnology Information Center: Properties, Applications, Research, and Safety Guidelines". American Elements. (Retrieved 13 May 2011).
4. Jayasena B, Subbiah S. "A novel mechanical cleavage method for synthesizing few-layer graphenes". Nanoscale Res Lett 2011; 6 (1): 9501.
5. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res 2011; 44: 875-82.
6. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today 2012; 17: 928-34.
7. Chen NT, Cheng SH, Souris JS. Theranostic applications of mesoporous silica nanoparticles and their organic/inorganic hybrids. J Mater Chem B 2013; 1: 3128-35.
8. Liu Z, Li Z. Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs). Theranostics 2014; 4: 990-01.
9. Gremse F, Theek B, Kunjachan S, et al. Absorption Reconstruction Improves Biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography. Theranostics 2014; 4: 960-71.
10. Jian J, Liu C, Gong Y, et al. India ink incorporated multifunctional phase-transition nanodroplets for photoacoustic/ultrasound dual modality imaging and photoacoustic effect based tumor therapy. Theranostics 2014; 4: 1026-38.
11. Fan CH, Lin WH, Ting CY, et al. Contrast-enhanced ultrasound imaging for the detection of focused ultrasound-induced bloodbrain barrier opening. Theranostics 2014; 4: 1014-25.
12. Cho IK, Moran SP, Paudyal R, et al. Longitudinal Monitoring of Stem Cell Grafts In vivo Using Magnetic Resonance Imaging with Inducible Maga as a Genetic Reporter. Theranostics 2014; 4: 972-89.
13. Zeng Z, Parekh P, Li Z, Shi ZZ, Tung CH, Zu Y. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics 2014; 4: 945-52.
14. Zhu J, Huang H, Dong S, Ge L, Zhang Y. Progress in aptamermediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics 2014; 4: 931-44.
15. Hondroulis E, Zhang R, Zhang C, et al. Immuno nanoparticles integrated electrical control of targeted cancer cell development using whole cell bioelectronic device. Theranostics 2014; 4: 919-30.
16. Draz MS, Fang BA, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014; 4: 872-92.
17. Deng H, Zhong Y, Du M, et al. Theranostic self-assembly structure of gold nanoparticles for nir photothermal therapy and x-ray computed tomography imaging. Theranostics 2014; 4: 904-18.
18. Jing L, Liang X, Li X, et al. Mn-porphyrin conjugated au nanoshells encapsulating doxorubicin for potential magnetic resonance imaging and light triggered synergistic therapy of cancer. Theranostics 2014; 4: 858-71.
19. Sun Y, Kim HS, Park J, et al. MRI of breast tumor initiating cells using the extra domain-b of fibronectin targeting nanoparticles. Theranostics 2014; 4: 845-57.
20. Hayashi K, Nakamura M, Miki H, et al. Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics 2014; 4: 834-44.
21. Turker NS, Heidari P, Kucherlapati R, Kucherlapati M, Mahmood U. An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. Theranostics 2014; 4: 893-03.
22. Sulek K, Han TL, Villas-Boas SG, et al. Hair metabolomics: identification of fetal compromise provides proof of concept for biomarker discovery. Theranostics 2014; 4: 953-59.
23. Mertens ME, Frese J, Bölü kbas DA, et al. FMN-coated fluorescent USPIO for cell labeling and non-invasive MR imaging in tissue engineering. Theranostics 2014; 4: 1002-13.
24. Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert Rev Mol Diagn 2013; 13: 257-69.
25. Clairambault J. Modelling physiological and pharmacological control on cell proliferation to optimise cancer treatments. Mathematical Modelling of Natural Phenomena 2009; 4: 12-67.
26. Ohdo S, Koyanagi S, Matsunga N. Chronopharmacological strategies: Intra-and inter-individual variability of molecular clock. Adv Drug Deliv Rev 2010; 62: 885-97.
27. Gajewicz A, Rasulev B, Dinadayalane TC, et al. Advancing risk assessment of engineered nanomaterials: Application of computational approaches. Adv Drug Deliv Rev 2012; 64: 1663-93.
28. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012; 64: 1394-16.
29. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products, Nanomedicine: Nanotech, Biol & Med 2013; 9: 1-14.
30. Kwon GS, Kataoka K. Block copolymer micelles as longcirculating drug vehicles. Adv Drug Deliv 2012; 64: 237-45.
31. Hansen S, Claus-Michael Lehr CM, Schaefer UF. Modeling the human skin barrier-Towards a better understanding of dermal absorption. Adv Drug Deliv Rev 2013; 65: 149-51.
32. Moghimi SM, Wibroe PP, Helvig SY, Farhangrazi SZ, Hunter AC. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward, Adv Drug Deliv Rev 2012; 64: 1385-93.
33. Kwon KC, Nityanandam R, Stewart J, Daniell H. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J 2013; 11: 77-86.
34. Chen L, Han L, Lian G. Recent advances in predicting skin permeability of hydrophilic solutes. Adv Drug Deliv Rev 2013; 65: 295-05.
35. Vig BS, Huttunen KM, Laine K, Rautio J. Amino acids as promoieties in prodrug design and development. Adv Drug Deliv Rev 2013; 65: 1375-85.
36. Shaikh S, Nazim S, Khan T, Shaikh A, Zameeruddin M, Quazi A. Recent Advances in Pulmonary Drug Delivery System: A Review. Int J Appl Pharm 2010; 2: 27-31.
37. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 1997; 28: 25-42.
38. Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm 2012; 81: 514-23.
39. Droumaguet BL, Nicolas J, Brambilla D, et al. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano 2012; 6: 5866-79.
40. Maksimenko A, Mougin J, Mura S, et al. Polyisoprenoyl gemcitabine conjugates self-assemble as nanoparticles, useful for cancer therapy. Cancer Lett 2013; 334: 346-53.
41. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005; 2: 108-19.
42. Chen X, Zaro JL, Shen WC. Fusion protein linkers: Property, design and functionality. Adv Drug Deliv Rev 2013; 65: 1357-69.
43. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 2013; 42: 1147-235.
44. Babinot J, Renard E, Droumaguet BL. Facile Synthesis of Multicompartment Micelles Based on Biocompatible Poly(3-hydroxyalkanoate). Macromol Rapid Commun 2013; 34: 362-8.
45. Nicholas A, Peppas NA. An introduction to the most cited papers in the history of Advanced Drug Delivery Reviews (1987-2012). Adv Drug Deliv Rev 2012; 48: 139-57.
46. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54: 3-12.
47. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995; 16: 215-33.
48. Lin WJ, Juang LW, Wang CL, Chen YC, Lin CC, Chang KL. Pegylated polyester polymeric micelles as a nano-carrier: synthesis, characterization, degradation, and biodistribution. J Expt & Clin Med 2010; 2: 4-10.
49. Vorup-Jensen T, Peer D. Nanotoxicity and the importance of being earnest. Adv Drug Deliv Rev 2012; 64: 1661-62.
50. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4(2): 219-33.
51. Stolnik L, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16: 195-14.
52. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 2011; 6: 765-74.
53. Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 2012; 64: 194-05.
54. Li X, Qi J, Xie Y, et al. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats. Int J Nanomed 2013; 8: 23-32.
55. Li XY, Kong XY, Shi S, et al. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotech 2008; 8: 89-100.
56. Dyondi D, Webster TJ, Banerjee R. A nanoparticulate injectable hydrogel as a tissue engineering scaffold for multiple growth factor delivery for bone regeneration. Int J Nanomed 2013; 8: 47-59.
57. Bhoyar N, Giri TK, Tripathi DK, Alexander A, Ajazuddin. Recent Advances in Novel Drug Delivery System Through Gels: Review. J Pharm & Allied Health Sci 2012; 2: 21-39.
58. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticlesto tumor microenvironment. Int J Nanomed 2013; 8: 61-71.
59. Wang J, Örnek-Ballanco C, Xu J, Yang W, Yu X. Preparation and characterization of vinculin-targeted polymer-lipid nanoparticle as intracellular delivery vehicle. Int J Nanomed 2013; 8: 39-46.
60. Lai F, Fadda AM, Sinico C. Liposomes for brain delivery. Expert opinion on Drug Deliv 2013; 10: 1003-22.
61. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013; 65: 1375-85.
62. Matsumura Y, Maeda H. "A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs". Cancer Res 1986; 46: 6387-92.
63. Duncan R, Sat YN. "Tumour targeting by enhanced permeability and retention (EPR) effect". Ann Oncol 1998; 9 (Suppl. 2): 39.
64. Vasey PA, Kaye SB, Morrison R, et al. "Phase I clinical and pharmacokinetic study of PK1[N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee". Clin Cancer Res 1999; 5: 83-94.
65. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25-37.
66. Griesh K. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? Drug Discov Today Technol 2012; 9: 161-6.
67. Poon RT, Borys N. "Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer". Expert Opin Pharmacother 2009; 10: 333-43.
68. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013; 73: 2412-17.
69. Kobayashi H, Rira Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2014; 4: 81-9.
70. Stapleton S, Milosevic M, Allen C, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLos One 2013; 8; E81157.
71. Bisht R. Chronomodulated drug delivery system: A comprehensive review on the recent advances in a new sub-discipline of 'chronopharmaceutics'. Asian J Pharm 2011; 5: 1-8.
72. Kulis M, Burks WA. Oral immunotherapy for food allergy: Clinical and preclinical studies. Adv Drug Deliv Rev 2013; 65: 774-81.
73. Chirra HD, Desai TA. Emerging microtechnologies for the development of oral drug delivery devices. Adv Drug Deliv Rev 2012; 64: 1569-78.
74. Wu CY, L. Z. Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
75. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: An overview. Adv Drug Deliv Rev 2013; 65: 1340-56.
76. Fernandes R, Gracias DH. Self-folding polymeric containers for encapsulation and delivery of drugs. Adv Drug Deliv Rev 2012; 64: 1579-89.
77. Zhang LY, Mena J, Sun J, et al. "Electrospray of multifunctional microparticles for image-guided drug delivery", Proc. SPIE 8233, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications IV, 823303 (February 9, 2012).
78. Peppas NA. Historical perspective on advanced drug delivery: How engineering design and mathematical modeling helped the field mature. Adv Drug Deliv Rev 2013; 65: 5-9.
79. Xu, S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances. Adv Drug Deliv Rev 2013; 65: 121-38.
80. Ekenseair AK, Kasper FK, Mikos AG. Perspectives on the interface of drug delivery and tissue engineering. Adv Drug Deliv Rev 2013; 65: 89-92.
81. Probst CE, Zrazhevsky P, Bagalkot V, Gao X. Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev 2013; 65: 703-19.
82. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-59.
83. Vizirianakis IS, Fatouros DG. Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements. Adv Drug Deliv Rev 2012; 64: 1359-62.
84. Wieland M, Fussenegger M. Reprogrammed cell delivery for personalized medicine. Adv Drug Deliv Rev 2013; 64: 1477-87.
85. Venditto VJ, Jr Szoka FC. Cancer nanomedicines: so many papers and so few drugs. Adv Drug Deliv Rev 2013; 65: 80-8.
86. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64: 1547-68.
87. Liu S. Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev 2013; 64: 1532-43.
88. Ryu JH, Koo H, Sun IC, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev 2012; 64: 1447-58.
89. Sawant RR, Jhaveri AM, Torchilin VP. Immunomicelles for advancing personalized therapy. Adv Drug Deliv Rev 2012; 64: 436-46.
90. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012; 64: 1394-1416.
91. Janowski M, Bulte JW, Walczak P, Personalized nanomedicine advancements for stem cell tracking. Adv Drug Deliv Rev 2012; 64: 1488-507.
92. Nicolini C, Bragazzi N, Pechkova E. Nanoproteomics enabling personalized nanomedicine. Adv Drug Deliv Rev 2012; 64: 1522-31.
93. Petersen AL, Hansen AE, Gabizon A, Andresen TL. Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev 2012; 64: 1417-35.
94. Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012; 64: 1508-21.
95. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631-51.
96. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev 2013; 65(1): 104-20.
97. Torchilin VP. Multifunctional Nanocarriers. Adv Drug Deliv Rev 2006; 58: 1532-55.
98. Rösler AA, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53: 95-108.
99. Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 2012; 64: 1363-84.
100. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
101. Ochoa M, Mousoulis C, Ziaie B. Polymeric microdevices for transdermal and subcutaneous drug delivery. Adv Drug Deliv Rev 2012; 64: 1603-16.
102. Stevenson CL, Santini Jr JT, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev 2012; 64: 1590-02.
103. Herrlich S, Spieth S, Messner S, Zengerle SR. Osmotic micropumps for drug delivery. Adv Drug Deliv Rev 2012; 64: 1617-27.
104. Meng E, Hoang T, MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications. Adv Drug Deliv Rev 2012; 64: 1628-38.
105. Li GH, Yang PP, Gao SS, Zu, YQ. Synthesis and micellar behavior of poly (acrylic acid-b-styrene) block copolymers. Coll Polymer Sci 2012; 290: 1825-31.
106. Li T, Evans AT, Chiravuri S, Gianchandani RY, Gianchandani YB. Compact, power-efficient architectures using microvalves and microsensors, for intrathecal, insulin, and other drug delivery systems. Adv Drug Deliv Rev 2012; 64: 1639-49.
107. Pararas EL, Borkholder DA, Borenstein JT. Microsystems technologies for drug delivery to the inner ear. Adv Drug Deliv Rev 2012; 64: 1650-60.
108. Brenneman M, Sharma S, Harting M, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cerebral Blood Flow & Metabolism 2010; 30: 140-9.
109. Yang B, Strong R, Sharma S, et al. Therapeutic Time Window and Dose-Response of Autologous Bone Marrow Mononuclear Cells for Ischemic Stroke. J Neurosci Res 2011; 89: 833-9.
110. Misra V, Yang B, Sharma S, Savitz S. Cell Based Therapy for Stroke. In Therapy for Neurological injury. Ed Charles S Cox Jr. Chapter 7, pp 143-162. Humana Press. Springer Science 2011.
111. Sharma S, Bing Y, Brenneman M, et al. Bone Marrow Mononuclear Cells Protect Neurons and Modulate Microglia in Cell Culture Models of Ischemic Stroke. J Neurosci Res 2010; 88: 2869-76.
112. Sharma S, Yang B, Xi X, J Grotta J, Aronowski J, Savitz S. IL-10 Directly Protects Cortical Neurons by Activating PI-3 Kinase and STAT-3 Pathways. Brain Res 2011; 1373: 189-94.
113. Khoury REl, Misra V, Sharma S, et al. The effect of Trans-Catheter Injections on Viability and Cytokine Release of Mononuclear Cells. Am J Neurorad 2010; 31; 1488-92.
114. Sharma S, and Ebadi M. In-Vivo Molecular Imaging in Parkinson's Disease. In Parkinson's Disease, Eds M. Ebadi and R. Pfieffer. Chapter 58, pp. 787-802, CRC Press Boca Rotan, Florida USA 2012.
115. Sharma S, Ebadi M. Therapeutic potential of metallothioneins as anti-inflammatory agents in polysubstance abuse. Inst Integ Omics Appl Biotech J 2011; 2: 50-61.
116. Sharma S, Ebadi M. Metallothioneins as early and sensitive biomarkers of redox signaling in neurodegenerative disorders. Inst Integ Omics Appl Biotech 2011; 2: 98-106.
117. Sharma S. Charnoly Body as a Sensitive Biomarker in Nanomedicine. International Translational Nanomedicine Conference, Boston, MASS, July 25-27, 2013.
118. Chabenne A, Moon C, Ojo C, Khogali A, Nepal B, Sharma S. Biomarkers in Fetal Alcohol Syndrome (Recent Update) Biomarkers & Genomic Med 2014; 6: 12-22.
119. Sharma S. Molecular pharmacology of environmental neurotoxins. in kainic acid: neurotoxic properties, biological sources, and clinical applications. p301, Chapter 85. Nova Science Publishers. New York.
120. Sharma S, Rais A, Sandhu R, Nel W, Ebadi M. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomed 2013; 8: 1477-88.
121. Sharma S, Ebadi M. Significance of Metallothioneins in Aging Brain. Neurochem Int 2014; 65: 40-48.
122. Sharma S, Nepal B, Moon CS, et al. Psychology of craving. Open Jr of Med Psych 2014; 3: 120-5.
123. Sharma S, Moon CS, Khogali A, et al. Biomarkers of Parkinson's Disease (Recent Update). Neurochem Int 2013; 63: 201-29.
124. Sharma S, Ebadi M. Charnoly body as Universal Biomarker of Cell Injury. Biomarkers & Genomic Med 2014; 6[epub ahead of print].
125. Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotide. Ther Deliv 2011; 2: 891-05.
126. Watkins J, Marsh A, Taylor PC, Singer DR. Personalized medicine: The impact on chemistry. Ther Deliv 2010; 1: 651-65.
127. Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010; 14: 520-28.
128. Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995; 2: 116-23.
129. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into erbb2-positive human breast cancer cells. Cancer Gene Ther 2001; 8: 555-65.
130. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol 2005; 23: 709-17.
131. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007; 104: 4095-100.
132. Wen WH, Liu JY, Qin WJ, et al. Targeted inhibition of hbv gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatol 2007; 46: 84-94.
133. Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134: 577-86.
134. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol. 2009; 27: 567-71.
135. Waite CL, Roth CM. Pamam-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem 2009; 20: 1908-16.
136. Kang H, Delong R, Fisher MH, Juliano RL. TAT-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005; 22: 2099-06.
137. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR. Tumor angiogenic vasculature targeting with pamam dendrimer-RGD conjugates. Chem Commun 2005; 46: 5739-41.
138. Kunath K, Merdan T, Hegener O, Haberlein H, Kissel T. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 2003; 5: 588-99.
139. Sioud M. Recent advances in small interfering RNA sensing by the immune system. Nat Biotechnol 2010; 27: 236-242.
140. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochem 2004; 43: 13233-41.
141. Leachman SA, Hickerson RP, Schwartz ME, et al. First-in-human mutation-targeted siRNA Phase Ib trial of an inherited skin disorder. Mol Ther 2010; 18: 442-6.
142. Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: A structural and functional outlook. Chem Med Chem 2010; 5: 328-49.
143. Avci CB, Baran Y. Use of microRNA in Personalized Medicine. M. Yousef and Allmer J (eds) miRNomics: MicroRNAs biology and Computational Analysis. Methods in Mol Biol 2013; 1107: 243-56. Springer Verlag Heidelberg Vol 1107.
144. Dreussi E, Biason P, Toffoli G, Cecchin E. miRNA pharmacogenomics: the new frontier for personalized medicine in cancer. Pharmacogenomics 2012; 13: 1635-50.
145. Fabbri M. MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med 2013; 3: 751-56.
146. Ibáñez-Ventoso C, Driscoll M. MicroRNAs in C. elegans Aging: Molecular Insurance for Robustness? Curr Genomics 2009; 10: 144-53.
147. Maes OC, Chertkow HM, Wang E, Schipper HM. MicroRNA: Implications for Alzheimer's disease and other human CNS disorders. Curr. Genomics 2010; 10: 154-68.
148. Klinge CM. Estrogen Regulation of MicroRNA Expression. Curr Genomics 2009; 10: 169-83.
149. Lie S, Morrison JL, Williams-Wyss O, et al. Periconceptional undernutrition programs changes in insulin-signaling molecules and microRNAs in skeletal muscle in singleton and twin fetal sheep. Biol Reprod 2014; 9; 90: 5.
150. Sookoian S, Gianotti TF, Burgueño AL, Pirola CJ. Fetal metabolic programming and epigenetic modifications: a systems biology approach. Pediat Res 2013; 73; 531-42.
151. Tomasetti M, Neuzil J, Dong L. MicroRNAs as regulators of mitochondrial function: role in cancer suppression. Biochim Biophys Acta 2014; 1840: 1441-53.
152. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009; 10: 273-84.
153. Lee RW, Shenoy DB, Sheel R. Micellar nanoparticles: applications for topical and passive transdermal drug delivery. 2010; Chapter 2: p 37-58. Handbook of Non-Invasive Drug Delivery Systems. (Non-Invasive and Minimally-Invasive Drug Delivery Systems for Pharmaceutical and Personal Care Products) A volume in Personal Care & Cosmetic Technology.
154. Wang E. MicroRNA Regulation and its Biological Significance in Personalized Medicine and Aging. Curr Genomics 2009; 10: 143.
155. Zhang M, Zhou X, Wang B, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release 2013; 168: 251-61.
156. Hamburg MA, Collins FC. The Path to Personalized Medicine. New Eng J Med 2010; 363: 301-4.